ID   BJAB-K43
AC   CVCL_IZ95
SY   BJAB K43; BJA-B K43; K43
DR   cancercelllines; CVCL_IZ95
DR   Wikidata; Q54796994
RX   PubMed=10334995;
RX   PubMed=10336988;
CC   Population: African; Kenyan.
CC   Virology: EBV-negative.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Groin; UBERON=UBERON_0008337.
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5711 ! BJAB
SX   Female
AG   5Y
CA   Cancer cell line
DT   Created: 15-05-17; Last updated: 05-10-23; Version: 10
//
RX   PubMed=10334995; DOI=10.1126/science.284.5418.1372;
RA   Keppler O.T., Hinderlich S., Langner J., Schwartz-Albiez R.,
RA   Reutter W., Pawlita M.;
RT   "UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation.";
RL   Science 284:1372-1376(1999).
//
RX   PubMed=10336988; DOI=10.1093/glycob/9.6.557;
RA   Keppler O.T., Peter M.E., Hinderlich S., Moldenhauer G., Stehling P.,
RA   Schmitz I., Schwartz-Albiez R., Reutter W., Pawlita M.;
RT   "Differential sialylation of cell surface glycoconjugates in a human B
RT   lymphoma cell line regulates susceptibility for CD95
RT   (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic
RT   virus.";
RL   Glycobiology 9:557-569(1999).
//